Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trevi Therapeutics ( (TRVI) ) has issued an announcement.
On August 14, 2025, Trevi Therapeutics announced that its Chief Financial Officer, Lisa Delfini, would resign from her position effective August 22, 2025. The company clarified that her departure was not due to any disagreements regarding company operations or policies. Jennifer L. Good, the company’s President and CEO, will temporarily assume the role of principal financial officer until a successor is appointed.
The most recent analyst rating on (TRVI) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Trevi Therapeutics stock, see the TRVI Stock Forecast page.
Spark’s Take on TRVI Stock
According to Spark, TipRanks’ AI Analyst, TRVI is a Neutral.
Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock’s technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.
To see Spark’s full report on TRVI stock, click here.
More about Trevi Therapeutics
Average Trading Volume: 1,912,362
Technical Sentiment Signal: Buy
Current Market Cap: $907.2M
For an in-depth examination of TRVI stock, go to TipRanks’ Overview page.